RE:RE:RE:RE:"...assess different market capitalization initiatives...""The pIpeline means absolutely nothing when have an incompetent person such as gagnon ruining oops running the show."
Gilles has done it. Avenanthramide was the original reason Gilles joined CZO. He has now advanced avenanthramide from an original vision, through to a purified powder used in the human exercise inflammation study validating immunological blood biomarkers, to a pharma-grade pill, to an approved human clinical trial with the Montreal Heart Institute and the influencial Dr. Jean-Claude Tardif. The clinical trial has now received final approval to begin enrollment as noted in the last news release and is expected to begin within the next ~30 days. CZO has the cash on hand and a trial protocol already approved to generate human clinical safety/tolerability, and preliminary efficacy data for the pill with Dr. Jean-Claude Tardif and the Montreal Heart Institute backing it. This data through to preliminary indications of efficacy is the basis for a potential bidding war between pharm for a license. CZO is the only producer of natural avenanthramide at scale in the world and the pill has also been investigated using PGX as a carrier with promising results.
Gilles has also delivered PGX from a university lab, through to the development of the prototype PGX-OBG, to the masterpiece PGX-YBG. This research has been supported significantly by the Canadian government. Dr. Kolb has now stated that if the results obtained for PGX-YBG in mice are reproduced in humans it will profoundly change the landscape for fibrosis treatment as stated in the news release. The importance of macrophages for fibrosis is well recognized in the scientific literature. Dr. Ask, who is now a leading translational scientist with the second largest pharma in the world, has previously expressed his excitement about CZO's masterpiece(PGX-YBG). The 'go / no go' clinical trial decision for fibrosis is expected this summer and summer officially begins in just 25 days.
From original vision, to product development, to clinical trial, from the avenanthramide pill, to PGX, Gilles is achieving the unprecedended. Given the risks of preclinical devlopment this is especially significant. The next milestones are opportunity and valuation defining and the company is now discussing strategies to capitalize the company.